Literature DB >> 4964844

Immunogenicity of an attenuated strain of vaccinia virus on rabbits and monkeys.

T Kitamura, Y Kitamura, I Tagaya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 4964844     DOI： 10.1038/2151187a0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  8 in total

1.  Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.

Authors:  Yasushi Ami; Yasuyuki Izumi; Kazuhiro Matsuo; Kenji Someya; Masaru Kanekiyo; Shigeo Horibata; Naoto Yoshino; Koji Sakai; Katsuaki Shinohara; Sohkichi Matsumoto; Takeshi Yamada; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

2.  Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.

Authors:  Minoru Kidokoro; Masato Tashiro; Hisatoshi Shida
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

3.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

4.  Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.

Authors:  Yasuyuki Izumi; Yasushi Ami; Kazuhiro Matsuo; Kenji Someya; Tetsutaro Sata; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

5.  Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs.

Authors:  Koji Ishii; Hideki Hasegawa; Noriyo Nagata; Tetsuya Mizutani; Shigeru Morikawa; Tetsuro Suzuki; Fumihiro Taguchi; Masato Tashiro; Toshitada Takemori; Tatsuo Miyamura; Yasuko Tsunetsugu-Yokota
Journal:  Virology       Date:  2006-05-06       Impact factor: 3.616

6.  Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control.

Authors:  Kazuhiro Matsuo; Yasuhiro Yasutomi
Journal:  Tuberc Res Treat       Date:  2011-05-24

Review 7.  Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

Authors:  Minoru Kidokoro; Hisatoshi Shida
Journal:  Vaccines (Basel)       Date:  2014-10-17

8.  Prime-boost immunization of codon optimized HIV-1 CRF01_AE Gag in BCG with recombinant vaccinia virus elicits MHC class I and II immune responses in mice.

Authors:  Duanthanorm Promkhatkaew; Nadthanan Pinyosukhee; Wilai Thongdeejaroen; Jantima Teeka; Preeda Wutthinantiwong; Preecha Leangaramgul; Pathom Sawanpanyalert; Paijit Warachit
Journal:  Immunol Invest       Date:  2009       Impact factor: 3.044
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.